DIABETES/METABOLISM RESEARCH AND REVIEWS RESEARCH ARTICLE Diabetes Metab Res Rev 2004; 20: 411â€“417. Published online 28 July 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/dmrr.499 Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limitingside effects in subjects with type 2 diabetes Mark S. Fineman Larry Z. Shen Kristin Taylor Dennis D. Kim Alain D. Baron* Amylin Pharmaceuticals, Inc., San Diego, CA, USA *Correspondence to: Alain D. Baron, Amylin Pharmaceuticals, Inc., 9360Towne Centre Dr., Suite 110, San Diego, CA 92121 USA. E-mail: abaron@amylin.com Received: 22 January 2004 Revised: 13 May 2004 Accepted: 14 May 2004Abstract Background Exenatide (exendin-4) exhibits dose-dependent glucoregula- tory activity, but causes dose-limiting nausea and vomiting. This study was